Algeta ASA is a pharmaceutical company with headquarters in Oslo. The company focuses on the development of innovative cancer treatments, particularly aimed at targeted therapy. Algeta has been involved in research and development of radiopharmaceuticals, which are medicines that use radioactive isotopes to treat cancer.
The company has achieved recognition for its contributions to oncology and has collaborated with various research institutions and companies to advance the development of its products. Algeta ASA has also been active in clinical studies to evaluate the effectiveness and safety of its treatments. The company's work has the potential to impact the treatment of several types of cancer, and they are part of the growing specialty drugs sector.